Ibrutinib and ABT199 for CLL

Jennifer Brown, MD, PhD

Video Categories: ASH 2014

Jennifer R. Brown, MD, PhD, at Dana-Farber Cancer Institute in Boston, discusses what she believes are the most important items coming out of ASH for CLL this year. She mentions excellent study results being presented about the drugs ibrutinib and ABT199.
January 4, 2017

Describing Side Effects on IV Therapy

Wouter de Herder, MD, discusses transient and long-term side effects for patients undergoing this type of treatment.

March 24, 2015

The Global Challenge of Personalized Medicines

Dr. Stainthorpe explains that when it comes to bringing personalized medicines to fruition, the challenge is the same worldwide. It is an effort that requires better understanding of disease pathways and markers as well as improved diagnostics.